Compass Therapeutics (NASDAQ:CMPX) Issues Earnings Results

Compass Therapeutics (NASDAQ:CMPX) posted its quarterly earnings data on Monday. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02), FiscalAI reports.

Here are the key takeaways from Compass Therapeutics’ conference call:

• Compass said it is funded through 2028 for its development programs and is focused on advancing its four clinical-stage drugs toward data milestones.
• In the COMPANION-002 trial, tovecimig more than tripled the response rate and improved progression-free survival (PFS hazard ratio 0.44), but the overall-survival endpoint was not met. More than half of control-arm patients crossed over; a crossover-adjusted analysis showed a 0.85 hazard ratio, but the FDA has recommended a study demonstrating a survival advantage, and the company said it has not discussed the feedback with the agency.
• Compass is seeking to re-engage with the FDA on tovecimig’s regulatory path, which could include accelerated approval with a confirmatory study, a full-approval discussion, or no approval based on current data. The company hopes to provide an update in the coming months.
• The company expects new pipeline updates: CTX-8371 expansion-cohort data by year-end, a possible CTX-10726 update before the January JPMorgan meeting, and a Phase II study of biomarker-selected CTX-471 in neuroendocrine tumors, with data expected later in 2027. These programs remain early-stage, and management said clinical data will be needed to establish differentiation.

Compass Therapeutics Stock Down 0.8%

CMPX opened at $0.83 on Wednesday. Compass Therapeutics has a 52-week low of $0.67 and a 52-week high of $6.88. The company has a 50 day moving average of $1.23 and a two-hundred day moving average of $3.05. The company has a market cap of $149.65 million, a P/E ratio of -1.77 and a beta of 1.06.

Analysts Set New Price Targets

Several research analysts have recently weighed in on CMPX shares. Wedbush dropped their price target on shares of Compass Therapeutics from $1.00 to $0.90 and set a “neutral” rating on the stock in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Thursday, October 15th. Citizens Jmp decreased their price objective on shares of Compass Therapeutics to $4.00 and set a “market outperform” rating on the stock in a research report on Wednesday, September 23rd. Lifesci Capital downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 22nd. Finally, Guggenheim decreased their target price on shares of Compass Therapeutics to $4.00 and set a “buy” rating for the company in a research report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.99.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer. Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.